Showing results (1141-1150 of 1,797) with videos related to
Sort By:
Pageof 180
Mabs|September 22, 2017
Going native: Direct high throughput screening of secreted full-length IgG antibodies against cell membrane proteinsYongliang Fang, Thach H Chu, Margaret E Ackerman, et al.Mabs|September 22, 2017
Suppressing allostery in epitope mapping experiments using millisecond hydrogen / deuterium exchange mass spectrometryBin Deng, Shaolong Zhu, Andrew M Macklin, et al.Mabs|September 28, 2017
Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptorsCaroline S Colley, Bojana Popovic, Sudharsan Sridharan, et al.Mabs|October 7, 2017
International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximabSandra Prior, Simon E Hufton, Bernard Fox, et al.Mabs|October 10, 2017
Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokineticsNicole M Piche-Nicholas, Lindsay B Avery, Amy C King, et al.Mabs|August 31, 2017
Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eyeDevin Tesar, Jacob Luoma, Emily A Wyatt, et al.Mabs|September 15, 2017
Nonspecificity in a nonimmune human scFv repertoireRyan L Kelly, Jessie Zhao, Doris Le, et al.Mabs|September 13, 2017
Glycan characterization of the NIST RM monoclonal antibody using a total analytical solution: From sample preparation to data analysisMark Hilliard, William R Alley, Ciara A McManus, et al.Mabs|December 5, 2015
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentJay Tibbitts, David Canter, Ryan Graff, et al.Mabs|December 15, 2015
Understanding differences between synthetic and natural antibodies can help improve antibody engineeringAnat Burkovitz, Yanay OfranPageof 180